Drug-Drug Interactions

Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have bee...

Celý popis

Uloženo v:

Podrobná bibliografie
Médium:	E-kniha
Jazyk:	angličtina
Vydáno:	Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
Témata:	(‒)-sophoranone 1A2 2B6 2C19 2C8 2C9 2D6 3A4 ADME adverse drug reactions biflavonoid Biology, life sciences chronic kidney disease competitive inhibition computational prediction CYP CYP1A1 CYP1A2 CYP2C9 CYP2D6 CYP3A CYP3A4 cytochrome P450 cytochromes P450 DDI Dexamethasone drug interaction drug interactions drug metabolism drug transporter drug-drug interaction drug-drug interactions expression fexofenadine gepants high plasma protein binding in silico in vitro in vivo inhibitor ixazomib Ketoconazole lasmiditan Lexicomp low permeability Loxoprofen Mathematics and Science mechanism-based inhibition metabolic DDI metabolism migraine monoclonal antibodies non-competitive inhibition O-desmethyltramadol OATP1B1 OATP1B3 organic anion transporting polypeptide 1A2 (OATP1A2) P-glycoprotein (P-gp) P450 pharmacokinetics physiologically-based pharmacokinetics plasma concentration polypharmacy potent inhibition QSAR Reference, Information and Interdisciplinary subjects regulation Research and information: general Rumex acetosa selamariscina A signal detection algorithms spontaneous reporting systems subset analysis substrate systemic exposure tadalafil ticagrelor tissue-specific tramadol tyrosine kinase inhibitors ubiquitination uridine 5′-diphosphoglucuronosyl transferase
ISBN:	9783036520353, 3036520368, 303652035X, 9783036520360
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb–drug or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions.
ISBN:	9783036520353 3036520368 303652035X 9783036520360
DOI:	10.3390/books978-3-0365-2036-0